Skip Navigation

European Heart Journal 1997 18(6):1024-1029;
Copyright © 1997 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Abdallah, A. N.
Right arrow Articles by Iron, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Abdallah, A. N.
Right arrow Articles by Iron, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1997 The European society of Cardiology

Evaluation of plasma levels of tumour necrosis factor alpha and interleukin-6 as rejection markers in a cohort of 142 heart-grafted patients followed by endomyocardial biopsy

A. N. Abdallah*, M. A. Billes{dagger}, Y. Attia*, C. Doutremepuich{dagger}, A. Cassaigne* and A. Iron*,

*Département de Biochimie Médicale et Biologie Moléculaire, Université de Bordeaux 2 and Laboratoire de Biochimie Hôpital Pellegrin, Bordeaux, France
{dagger}Service de Cardiochirurgie, Hôpital Haut-Lévêque Pessac, France

Received 12 July 1996; accepted 18 July 1996.

Correspondence: Dr A. Iron. Département de Biochimie Médicale et Biologie Moléculaire, Université de Bordeaux 2, 146 rue Léo-Saignat. 33076 Bordeaux Cédex. France

Abstract

The rejection reaction after cell or organ transplantation has to be detected as early as possible in order to conduct optimal immunosuppressive treatment. Among the numerous events leading to rejection, cytokine production, especially of tumour necrosis factor alpha, is particularly important. Interleukin-6 and tumour necrosis factor alpha were investigated in 142 heart-grafted patients in order to define an early peripheral non-invasive marker of an acute rejection that could fit well with myocardial biopsy results. Cytokines were immunoenzymatically measured in blood specimens collected on the day of the endomyocardial biopsy. The values were compared to the grade of heart graft rejection established according to pathological criteria. Plasma interleukin-6 and especially tumour necrosis factor alpha determined on the day of the rejection diagnosis were significantly increased in the patient sample with moderate or severe rejection when compared with mean values of interleukin-6 and tumour necrosis factor alpha in the patient sample without rejection or with mild rejection (P=0·04 and 0·001 respectively). Because high levels of tumour necrosis factor alpha may appear before histological signs, this biological marker could be useful in the follow-up of heart-grafted patients.

Key Words: Cardiac transplantation • heart-graft rejection • tumour necrosis factor alpha • interleukin-6


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
S Metyas, D La, and D G Arkfeld
The use of the tumour necrosis factor antagonist infliximab in heart transplant recipients: two case reports
Ann Rheum Dis, November 1, 2007; 66(11): 1544 - 1545.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
C. C. Canver and J. Chanda
Heart transplantation
Ann. Thorac. Surg., August 1, 2001; 72(2): 658 - 660.
[Full Text] [PDF]

Home page
 CirculationHome page
M. S. Eisenberg, H. J. Chen, M. K. Warshofsky, R. R. Sciacca, H. S. Wasserman, A. Schwartz, and L. E. Rabbani
Elevated Levels of Plasma C-Reactive Protein Are Associated With Decreased Graft Survival in Cardiac Transplant Recipients
Circulation, October 24, 2000; 102(17): 2100 - 2104.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. Shimizu, U. Schonbeck, F. Mach, P. Libby, and R. N. Mitchell
Host CD40 Ligand Deficiency Induces Long-Term Allograft Survival and Donor-Specific Tolerance in Mouse Cardiac Transplantation But Does Not Prevent Graft Arteriosclerosis
J. Immunol., September 15, 2000; 165(6): 3506 - 3518.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
M. Azzawi and P. Hasleton
Tumour necrosis factor alpha and the cardiovascular system: its role in cardiac allograft rejection and heart disease
Cardiovasc Res, September 1, 1999; 43(4): 850 - 859.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.